Uncategorized - December 8, 2014
Virus May Cause Type 1 Diabetes
Researchers have found a virus in the pancreas of patients with type 1 diabetes. The discovery may offer the potential for both treatment and a vaccine. For many years it has been suspected that a virus is a possible cause of type 1 diabetes. A new study has found a virus present in the pancreas […]
Clinical Trials - December 8, 2014
Bavarian Nordic vs Ebola
Denmark’s Bavarian Nordic announced Dec. 4 that a first subject has been dosed with MVA-BN Filo in a Phase 1 safety and immunogenicity trial, evaluating a heterologous prime-boost regimen of Ebola candidate vaccines. The trial, sponsored by the University of Oxford, is assessing the monovalent cAd3-EBO Z vaccine co-developed by GSK and the U.S. National […]
Regulatory compliance - December 8, 2014
Meda, Cipla Suing Apotex
Meda Pharmaceuticals Inc. and Cipla Ltd. announced recently that they sued Apotex Inc. and Apotex Corp. in U.S. Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray in response to Apotex’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA), and […]
Companies - December 5, 2014
Flamel, Recipharm to Partner
Flamel Technologies announced that it has entered into an agreement to divest its development and manufacturing facility located in Pessac, France, to RecipharmAB. Under the agreement, Recipharm will pay Flamel EUR 10.6 million and make an investment of EUR 10.5 million in Flamel’s stock upon the closing of deal at a purchase price equal to […]
Companies - December 5, 2014
Meda to Stop Making Penicillin in Sweden
Meda, one of Recipharm’s customers, has today advised that it will transfer supply of its mainly Swedish penicillin products and manufacture offshore with other suppliers. The manufacturing contract with Recipharm Strängnäs will be terminated on Dec. 31, 2015. This business accounts for approximately 2% of Recipharm’s current sales. Recipharm currently employs 60 employees in Strängnäs and unfortunately the […]
Collaboration - December 5, 2014
Nanovector, Affibody to Collaborate
Norway’s Nordic Nanovector ASA and Sweden’s Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant, the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary […]
